9N3H | pdb_00009n3h

Crystal structure of HBV capsid with compound 18


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.54 Å
  • R-Value Free: 
    0.297 (Depositor), 0.299 (DCC) 
  • R-Value Work: 
    0.261 (Depositor), 0.270 (DCC) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 9N3H

Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history

Literature

Discovery of VNRX-9945, a Potent, Broadly Active Capsid Assembly Modulator as a Clinical Candidate for the Treatment of Chronic Hepatitis B Virus Infection.

Liu, B.Yao, J.Haimowitz, T.Benetatos, C.A.Boyd, S.A.Condon, S.M.Burns, C.J.White, A.Lakshminarasimhan, D.Suto, R.K.Cakici, O.Drager, A.S.Hart, S.G.E.Pevear, D.C.Coburn, G.A.

(2025) ACS Med Chem Lett 16: 1209-1216

  • DOI: https://doi.org/10.1021/acsmedchemlett.5c00315
  • Primary Citation Related Structures: 
    9N3H

  • PubMed Abstract: 

    Targeting the capsid protein of the hepatitis B virus (HBV) has emerged as a promising strategy for developing new antiviral therapies. In this study, we report the discovery of a novel series of pyrrole oxo-carboxamide compounds as HBV capsid assembly modulators (CAMs) that block viral replication. Through a process of focused structure-activity relationship (SAR) optimization, we identified compound 12 (VNRX-9945), which exhibited excellent and broad antiviral activity against multiple HBV genotypes in vitro, along with favorable pharmacokinetic profiles across multiple species. Additionally, 12 demonstrated robust efficacy in the adeno-associated virus mouse model of HBV (AAV-HBV) infection. This compound has advanced into Phase 1 clinical trials to evaluate its safety and pharmacokinetics in healthy volunteers, to enable treatment of chronic HBV infections.


  • Organizational Affiliation
    • Venatorx Pharmaceuticals, Inc., 30 Spring Mill Drive, Malvern, Pennsylvania 19355, United States.

Macromolecule Content 

  • Total Structure Weight: 36.9 kDa 
  • Atom Count: 2,188 
  • Modeled Residue Count: 268 
  • Deposited Residue Count: 320 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Capsid protein
A, B
160Hepatitis B virus subtype adywMutation(s): 1 
Gene Names: C
UniProt
Find proteins for P03147 (Hepatitis B virus genotype D subtype adw (isolate United Kingdom/adyw/1979))
Explore P03147 
Go to UniProtKB:  P03147
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP03147
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
A1BVU
(Subject of Investigation/LOI)

Query on A1BVU



Download:Ideal Coordinates CCD File
C [auth A],
D [auth B]
N-[3-(difluoromethyl)phenyl]-5-[{[(1s,4s)-4-hydroxycyclohexyl]amino}(oxo)acetyl]-1,2,4-trimethyl-1H-pyrrole-3-carboxamide
C23 H27 F2 N3 O4
ZUNIWKRJDDBEPY-WOVMCDHWSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.54 Å
  • R-Value Free:  0.297 (Depositor), 0.299 (DCC) 
  • R-Value Work:  0.261 (Depositor), 0.270 (DCC) 
Space Group: H 3 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 88.152α = 90
b = 88.152β = 90
c = 290.557γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Other privateUnited States--

Revision History  (Full details and data files)

  • Version 1.0: 2025-07-02
    Type: Initial release
  • Version 1.1: 2025-07-30
    Changes: Database references